Clinical Trial Update: BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 clinical trial of BNC105P in partially platinum-sensitive ovarian cancer patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BNC105P (BNC105P)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: WITHDRAWN